Choose Your language:
- Social bookmarks:
- Testimonials
-
Thank you for your follow up,
I did receive the pills and had an opportunity to try them. I am very
happy, so is my girlfriend.
Thanks
- DN
Read more »
Our billing is certified by:
- News
-
- FDA approved Tadalafil medication for the treatment of erectile dysfunction accompanied with primary and secondary symptoms of benign prostatic hyperplasia (BPH) in men above 45 years.
- Considering the information of three randomized, multicenter, double, blind clinical studies and a retrospective analysis of the medical documentation, FDA approved on October 7, 2011 Tadalafil medication for the treatment of erectile dysfunction accompanied with primary and secondary symptoms of benign prostatic hyperplasia (BPH) in men above 45 years
- The forming, development and monitoring of the pharmaceutical market in USA in September 2011
- In spite of low rates and stagnation of industrial development, the pharmaceutical market shows a dynamical growth
- Sildenafil citrate and pulmonary arterial hypertension
- Pulmonary arterial hypertension Definition “pulmonary arterial hypertension” is related to a group of diseases characterized by: - Progressive increase in pulmonary vascular resistance; - Reduction in pulmonary bloodflow; - High pulmonary artery pressure; - Contractility of the heart right ventricle; - Right ventricular failure
- Fruit and vegetables do not reduce overall cancer risk, review concludes
- Eating lots of fruit and vegetables will do little to reduce your risk of developing cancer, according to a review of a decade of research involving more than a million people
- Common painkillers could be linked to male reproductive disorder
- The use of mild painkillers, such as paracetamol, in pregnancy – previously considered harmless to the baby in the womb – could be a major factor in the rise of male reproductive disorders, according to a study
-
- FDA Rejects Loxapine for Approval - Medscape
- RTT NewsFDA Rejects Loxapine for ApprovalMedscapeMay 5, 2012 — The US Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) saying that the new drug application for loxapine inhalation powder (Adasuve, Alexza Pharmaceuticals, Inc) is not ready for approval in its current
- Common antipsychotic drugs - GazetteNET
- Common antipsychotic drugsGazetteNETBy THE DAILY HAMPSHIRE GAZETTE Abilify (aripiprazole), Clozaril (clozapine), Fanapt (iloperidone), fluphenazine (generic only), Geodon (ziprasidone), Haldol (haloperidol), Invega (paliperidone), Loxitane (loxapine), Moban (molindone),
- Benzinga's Microcap Movers for Friday May 4, 2012 - Benzinga
- Benzinga's Microcap Movers for Friday May 4, 2012BenzingaAlexza Pharmaceuticals announced Thursday that it had received a Complete Response Letter from the US Food and Drug Administration regarding its New Drug Application for ADASUVE (loxapine) inhalation powder, 5 mg and 10 mg
- Alexza Reports 2012 First Quarter Financial Results and Provides Business Update - MarketWatch (press release)
- Alexza Reports 2012 First Quarter Financial Results and Provides Business UpdateMarketWatch (press release)
- Biotech Industry Hotbed of Merger & Acquisition Speculation - MarketWatch (press release)
- Biotech Industry Hotbed of Merger & Acquisition SpeculationMarketWatch (press release)The company recently received a Complete Response Letter (CRL) from the US Food and Drug Administration (FDA) regarding its New Drug Application for ADASUVE (loxapine) inhalation powder
